Feb 3(Reuters) – Pfizer on Tuesday reported fourth-quarter profit above Wall Street estimates, as sustained demand for older drugs such as blood thinner Eliquis helped offset fading sales of its COVID products.
The upbeat results land as Pfizer navigates falling demand for its COVID-19 products and faces the upcoming patent expirations on several of its older drugs, which will allow cheaper generics to enter the market.
Pfizer has already warned of challenges it expects over the next few years and has said that it does not expect to return to revenue growth until 2029. The company is banking on developing
Our publication features several staff writers, allowing us to report on different events and offer expert perspectives across various subjects.